Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals

BACKGROUND & AIMS: The approval of all-oral direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) has led to the expansion of therapy to include patients with cirrhosis who have hepatocellular carcinoma (HCC). Data on the use of DAAs in HCV+ patients with HCC is lim...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Hepatol
Main Authors: Prenner, Stacey B., VanWagner, Lisa B., Flamm, Steven L., Salem, Riad, Lewandowski, Robert J., Kulik, Laura
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776681/
https://ncbi.nlm.nih.gov/pubmed/28161470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2017.01.020
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares